Sebum Metabolomics and Lipidomics for Clinical Applications
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age20+
SponsorNational Taiwan University Hospital
About this trial
This study aims to develop a standardized workflow for sebum sampling and metabolomics/lipidomics analysis using Sebutape. A total of 200 participants will be recruited, including healthy individuals, patients with skin diseases, individuals undergoing dermatological treatments or using skincare products, and a subset of healthy participants receiving short-term topical antibiotic intervention. The study will investigate sebum composition, skin microbiome profiles, and their interactions under different conditions to explore potential biomarkers and clinical applications.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Individuals aged ≥20 years, regardless of sex or ethnicity, and assessed by the investigator to be in good health and suitable for participation.
No diagnosed skin diseases or chronic systemic diseases.
No use of medications or receipt of dermatological treatments that may affect sebum secretion or the skin microbiome within the past two weeks.
Disqualifiers
Known allergy to Sebutape or similar adhesive tapes, or a history of related adverse reactions.
Presence of acute or chronic skin diseases, or chronic systemic diseases.
Use of medications or receipt of dermatological treatments that may affect sebum secretion or the skin microbiome within the past two weeks.
Use of lotions, sunscreen, or other skincare products that may affect skin condition within 12 hours prior to sampling.
Trial design
Design model
Single group
Treatments tested in this trial
Sebutape sampling
Other interventionNon-invasive sebum sampling using Sebutape patches. Each participant will undergo standardized sampling procedures, with one patch used for metabolomics/lipidomics analysis and another for microbiome profiling. Samples will be stored at -80 °C for subsequent LC-MS/MS and 16S rRNA sequencing.
Bacitracin/Polymyxin B/Neomycin ointment (Yentuogin ointment)
DrugShort-term topical antibiotic intervention using Yentuogin ointment containing Bacitracin, Polymyxin B, and Neomycin. Healthy participants will apply the ointment 1-2 times daily for up to 3 days. Sebutape samples will be collected before and after intervention to assess changes in sebum composition and skin microbiome.
Treatment groups
200 Participants
are divided into 1 treatment groupGroup A: Sebutape sampling and analysisExperimental treatment 2 interventions
Trial outcomes
Primary outcomes
1
Concentration of Sebum Lipids Measured by LC-MS/MS
Sebum lipid levels will be measured using Sebutape sampling followed by LC-MS/MS analysis. Results will be reported as normalized intensity.
Time frame
From baseline (pre-intervention or pre-treatment) to post-intervention (approximately 1 day after completion of a 3-day intervention) or post-treatment (up to 3 months after treatment initiation, depending on treatment regimen)2
Relative Abundance of Skin Microbiome Composition Assessed by Sequencing
Skin microbiome profiles will be assessed using sequencing-based analysis and reported as relative abundance (%).
Time frame
From baseline (pre-intervention or pre-treatment) to post-intervention (approximately 1 day after completion of a 3-day intervention) or post-treatment (up to 3 months after treatment initiation, depending on treatment regimen)Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: